HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
STX16
syntaxin 16
Chromosome 20 · 20q13.32
NCBI Gene: 8675Ensembl: ENSG00000124222.24HGNC: HGNC:11431UniProt: B4DJX9
76PubMed Papers
21Diseases
0Drugs
3Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneTransporter
CLINICAL
OMIM Disease Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
Golgi cisternaSNAP receptor activityprotein bindingsyntaxin bindingpseudohypoparathyroidism type 1Bfemale reproductive system diseasemenopausal or post-menopausal diseaseportal hypertension
✦AI Summary

STX16 (syntaxin 16) is a SNARE protein involved in vesicular trafficking, specifically mediating membrane fusion during retrograde transport from late endosomes to the trans-Golgi network 1. As a SNARE complex component, STX16 functions in vesicle docking and fusion processes essential for intracellular protein transport 1. The primary clinical significance of STX16 relates to its role as an imprinting control region (STX16-ICR) regulating the GNAS locus on chromosome 20.3. Maternal microdeletions or deletions of STX16 cause autosomal dominant pseudohypoparathyroidism type 1B (PHP1B) 234. These STX16 deletions disrupt the imprinting control region, leading to loss of methylation at the GNAS exon A/B differentially methylated region, resulting in biallelic expression of A/B transcripts and reduced Gsα (stimulatory G protein alpha-subunit) expression 25. The STX16-ICR functions as a biallelically active embryonic enhancer that controls allele-specific chr20 conformations and GNAS promoter activity, with pathogenicity dependent on maternal inheritance 6. This epigenetic dysregulation causes multihormone resistance, particularly to parathyroid hormone and thyroid-stimulating hormone, manifesting as PHP1B with hypocalcemia and hyperphosphatemia 34. Beyond imprinting disorders, STX16 is upregulated in clear cell renal cell carcinoma, where it promotes tumor progression and immune modulation 7.

Sources cited
1
STX16 is a SNARE family member mediating membrane fusion and vesicular trafficking; chromosomal microdeletions involving STX16 cause PHP1B associated with abnormal GNAS imprinting
PMID: 32959907
2
Maternal deletions within STX16 cause AD-PHP1B by disrupting the imprinting control region and causing loss of methylation at GNAS exon A/B
PMID: 33529330
3
STX16 mutations (deletions, duplications, insertions, inversions) cause PHP1B through epigenetic changes at GNAS differentially methylated regions, leading to hormonal resistance via impaired Gsα expression
PMID: 37965945
4
Maternal STX16 deletion causes familial PHP1B with heterogeneous clinical presentation including hypocalcemia, TSH resistance, and variable bone abnormalities
PMID: 35119251
5
Heterozygous maternal deletions within STX16 cause AD-PHP1B through loss-of-methylation at GNAS exon A/B, reducing Gsα expression and causing hormonal resistance
PMID: 27995443
6
STX16-ICR acts as a biallelically active embryonic enhancer controlling GNAS imprinting through allele-specific chromatin conformations; microdeletions cause PHP1B upon maternal but not paternal inheritance
PMID: 39910084
7
STX16 gene contains the imprinting center of the GNAS locus; maternal deletions cause methylation anomalies responsible for PHP1B through loss of Gsα expression
PMID: 19942373
8
STX16 is upregulated in clear cell renal cell carcinoma and promotes tumor progression, migration, invasion, and immune infiltration modulation
PMID: 41266441
Disease Associationsⓘ21
pseudohypoparathyroidism type 1BOpen Targets
0.64Moderate
female reproductive system diseaseOpen Targets
0.36Weak
menopausal or post-menopausal diseaseOpen Targets
0.35Weak
chronic laryngitisOpen Targets
0.24Weak
portal hypertensionOpen Targets
0.24Weak
intracranial hemorrhageOpen Targets
0.20Weak
genetic disorderOpen Targets
0.19Weak
Varicose veinsOpen Targets
0.19Weak
autosomal dominant pseudohypoaldosteronism type 1Open Targets
0.17Weak
neoplasmOpen Targets
0.05Suggestive
nonpapillary renal cell carcinomaOpen Targets
0.05Suggestive
facial painOpen Targets
0.04Suggestive
diabetes mellitus, permanent neonatal 4Open Targets
0.04Suggestive
cystOpen Targets
0.04Suggestive
permanent neonatal diabetes mellitus 1Open Targets
0.03Suggestive
Glycogen storage disease due to hepatic glycogen synthase deficiencyOpen Targets
0.03Suggestive
maturity-onset diabetes of the young type 13Open Targets
0.03Suggestive
MODYOpen Targets
0.03Suggestive
glutaric acidemia type 3Open Targets
0.03Suggestive
Abnormality of the skeletal systemOpen Targets
0.03Suggestive
Pseudohypoparathyroidism 1BUniProt
Pathogenic Variants3
NM_001001433.3(STX16):c.556+1G>APathogenic
Pseudohypoparathyroidism type 1B
★☆☆☆2025
NM_001001433.3(STX16):c.393+557_792+364delPathogenic
Pseudohypoparathyroidism type 1B
★☆☆☆2020
NM_001001433.3(STX16):c.145-2060_556+343delPathogenic
Pseudohypoparathyroidism type 1B
☆☆☆☆2005
View on ClinVar ↗
Related Genes
GOLGA1Protein interaction100%RAB6AProtein interaction100%SNAP23Protein interaction100%BNIP1Protein interaction100%NSFProtein interaction100%SNAP25Protein interaction100%
Tissue Expression6 tissues
Ovary
100%
Bone Marrow
96%
Liver
79%
Lung
77%
Heart
54%
Brain
39%
Gene Interaction Network
Click a node to explore
STX16GOLGA1RAB6ASNAP23BNIP1NSFSNAP25
PROTEIN STRUCTURE
Preparing viewer…
PDB8QQF · 2.19 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.98LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.70 [0.52–0.98]
RankingsWhere STX16 stands among ~20K protein-coding genes
  • #6,290of 20,598
    Most Researched76
  • #4,023of 5,498
    Most Pathogenic Variants3
  • #9,302of 17,882
    Most Constrained (LOEUF)0.98
Genes detectedSTX16
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Molecular Definition of Pseudohypoparathyroidism Variants.
PMID: 33529330
J Clin Endocrinol Metab · 2021
1.00
2
SNAREs and developmental disorders.
PMID: 32959907
J Cell Physiol · 2021
0.90
3
Pseudohypoparathyroidism: complex disease variants with unfortunate names.
PMID: 37965945
J Mol Endocrinol · 2024
0.80
4
A biallelically active embryonic enhancer dictates GNAS imprinting through allele-specific conformations.
PMID: 39910084
Nat Commun · 2025
0.70
5
Integrative analysis identifies STX16 as a prognostic and immune-associated biomarker in ccRCC.
PMID: 41266441
Sci Rep · 2025
0.60